Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

• Results Overview

  Adding dupilumab to standard steroid cream treatment for 1 year significantly improved eczema symptoms compared to using steroid cream alone, with acceptable safety.

• Study Summary

  Num Participants:

  740

  Study Type:

  Rct

  Control Group:

  Placebo Plus Topical Corticosteroids

  Efficacy End Points Treatment:

  {'IGA 0/1': 39, 'EASI-75': 69}

  Efficacy End Points Control:

  {'IGA 0/1': 12, 'EASI-75': 23}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Injection-Site Reactions	Low
  Conjunctivitis	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected